Memo Therapeutics Email Formats
Biotechnology Research • 
Schlieren, Zurich, Switzerland • 21-50 Employees
Memo Therapeutics Email Formats
Memo Therapeutics uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@memo-therapeutics.com), used 55% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@memo-therapeutics.com | 55% |
{first initial}.{last name} | j.doe@memo-therapeutics.com | 45% |
Key Contacts at Memo Therapeutics
Erik Van Den Berg
Ceo
Lowell Brady
Director Of Analytical Development And Quality Control
Danielle Forkink
Assoc. Director, Clinical Operations
Matthias Hillenbrand
Director Of Virology
Company overview
| Headquarters | Wagistrasse 27, Schlieren, Zurich 8952, CH |
| Phone number | +41445159140 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Infectious Disease, Antibody Discovery, Human Antibodies, High Throughput, Therapeutic Antibodies, Antibodyome, Antibody Repertoire, Single B Cell |
| Founded | 2012 |
| Employees | 21-50 |
| Socials |
About Memo Therapeutics
Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Memo Therapeutics has 15 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Memo Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Memo Therapeutics Tech Stack
Discover the technologies and tools that power Memo Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
Form builders
Hosting
JavaScript libraries
JavaScript libraries
Maps
WordPress themes
Page builders
JavaScript libraries
Web servers
Font scripts
United States
Belgium
France
United Kingdom
MexicoFrequently asked questions
4.8
40,000 users
